RESUMO
The multifactorial basis of therapeutic response can obscure the relation between antimicrobial drug susceptibility and clinical outcome. To discern the relationship between parasite susceptibility to meglumine antimoniate (SbV) and therapeutic outcome of cutaneous leishmaniasis, risk factors for treatment failure were considered in evaluating this relationship in ninety-one cutaneous leishmaniasis patients and corresponding clinical strains of Leishmania (Viannia) panamensis. Parasite susceptibility to 32 µg SbV/mL (plasma Cmax) was evaluated in primary human macrophages, PBMCs, and U937 macrophages. Early parasitological response to treatment was determined in lesions of a subgroup of patients, and pathogenicity of Sb-resistant and sensitive clinical strains was compared in BALB/c mice. Parasite survival in cell models and patient lesions was determined by qRT-PCR of Leishmania 7SLRNA transcript. Parasite loads in BALB/c mice were quantified by limiting dilution analysis. The disparate Sb-susceptibility of parasite subpopulations distinguished by isoenzyme profiles (zymodemes) was manifest in all cell models. Notably, Sb-resistance defined by parasite survival, was most effectively discerned in U937 macrophages compared with primary human host cells, significantly higher among strains from patients who failed treatment than cured and, significantly associated with treatment failure. Each unit increase in transformed survival rate corresponded to a 10.6-fold rise in the odds of treatment failure. Furthermore, treatment failure was significantly associated with naturally Sb-resistant zymodeme 2.3 strains, which also produced larger lesions and parasite burdens in BALB/c mice than Sb-sensitive zymodeme 2.2 strains. The confounding effect of host risk factors for treatment failure in discerning this association was evidenced in comparing strains from patients with and without the defined risk factors for treatment failure. These results establish the association of natural resistance to meglumine antimoniate with treatment failure, the importance of host risk factors in evaluating drug susceptibility and treatment outcome, and the clinical and epidemiological relevance of natural Sb-resistance in L. (V.) panamensis subpopulations.
Assuntos
Antiprotozoários , Resistência a Medicamentos , Leishmaniose Cutânea , Macrófagos , Antimoniato de Meglumina , Meglumina , Camundongos Endogâmicos BALB C , Compostos Organometálicos , Falha de Tratamento , Animais , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/parasitologia , Antimoniato de Meglumina/uso terapêutico , Antimoniato de Meglumina/farmacologia , Humanos , Antiprotozoários/uso terapêutico , Antiprotozoários/farmacologia , Feminino , Meglumina/uso terapêutico , Meglumina/farmacologia , Compostos Organometálicos/uso terapêutico , Compostos Organometálicos/farmacologia , Camundongos , Macrófagos/parasitologia , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Masculino , Leishmania guyanensis/efeitos dos fármacos , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Carga Parasitária , AdolescenteRESUMO
Besides being scarce, the drugs available for treating cutaneous leishmaniasis have many adverse effects. Ozone is an option to enhance the standard treatment due to the wound-healing activity reported in the literature. In this study, we evaluated the efficiency of ozonated sunflower oil as an adjuvant in treating cutaneous lesions caused by Leishmania amazonensis. BALB/c mice were infected with L. amazonensis, and after the lesions appeared, they were treated in four different schedules using the drug treatment with meglumine antimoniate (Glucantime®), with or without ozonated oil. After thirty days of treatment, the lesions' thickness and their parasitic burden, blood leukocytes, production of NO and cytokines from peritoneal macrophages and lymph node cells were analyzed. The group treated with ozonated oil plus meglumine antimoniate showed the best performance, improving the lesion significantly. The parasitic burden showed that ozonated oil enhanced the leishmanicidal activity of the treatment, eliminating the parasites in the lesion. Besides, a decrease in the TNF levels from peritoneal macrophages and blood leukocytes demonstrated an immunomodulatory action of ozone in the ozonated oil-treated animals compared to the untreated group. Thus, ozonated sunflower oil therapy has been shown as an adjuvant in treating Leishmania lesions since this treatment enhanced the leishmanicidal and wound healing effects of meglumine antimoniate.
Assuntos
Antiprotozoários , Leishmaniose Cutânea , Ozônio , Animais , Camundongos , Antimoniato de Meglumina/farmacologia , Antimoniato de Meglumina/uso terapêutico , Óleo de Girassol/uso terapêutico , Antiprotozoários/farmacologia , Meglumina/farmacologia , Meglumina/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/parasitologia , Cicatrização , Ozônio/uso terapêutico , Camundongos Endogâmicos BALB CRESUMO
Hexagonal liquid crystals and supramolecular polymers from meglumine-based supra-amphiphiles were developed as drug delivery systems to be applied on the skin. The influence of fatty acid unsaturation on the structure and mechanical properties was evaluated. Moreover, we have investigated the system biocompatibility and how the type of water could influence its bioadhesive properties. Meglumine-oleic acid (MEG-OA) was arranged as hexagonal liquid crystals at 30-70â¯wt% water content, probably due to its curvature and increased water solubility. Meglumine-stearic acid (MEG-SA) at 10-80â¯wt% water content self-assembled as a lamellar polymeric network, which can be explained by the low mobility of MEG-SA in water due to hydrophobic interactions between fatty acid chains and H-bonds between meglumine and water molecules. Both systems have shown suitable mechanical parameters and biocompatibility, making them potential candidates to encapsulate therapeutic molecules for skin delivery. Moreover, a strong positive correlation between the amount of unfrozen bound water in meglumine-based systems and the bioadhesion properties was observed. This work shows that a better understanding of the physicochemical properties of a drug delivery system is extremely important for the correlation with the desired biological response and, thus, improve the product performance for biomedical applications.
Assuntos
Sistemas de Liberação de Medicamentos , Meglumina/química , Pele/química , Tensoativos/química , Água/química , Adesão Celular , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Meglumina/síntese química , Meglumina/farmacologia , Tamanho da Partícula , Relação Estrutura-Atividade , Propriedades de Superfície , Tensoativos/síntese química , Tensoativos/farmacologia , ViscosidadeRESUMO
Epoxymethoxylawsone is a naphthoquinone derivative promising as drug candidate for the treatment of leishmaniases. In the present work the effectiveness of epoxymethoxylawsone, and meglumine antimoniate on Leishmania (Leishmania) amazonensis parasites and on mice paw lesions of infected BALB/c mice was assessed. In an intracellular amastigotes assay, the half-maximal inhibitory concentration (IC50) value for epoxymethoxylawsone was slightly higher (1.7-fold) than that found for meglumine antimoniate. The efficacy of both drugs became more evident after 48 h of exposure when either the oxirane compound and reference drug reached 18-fold and 7.4-fold lower IC50 values (0.40 ± 0.001 µM and 0.60 ± 0.02 µM), respectively. Promastigotes were also affected by epoxymethoxylawsone after 24 h of incubation (IC50 = 45.45 ± 5.0 µM), but with IC50 6-fold higher than those found for intracellular amastigotes. Cytotoxicity analysis revealed that epoxymethoxylawsone (CC50 = 40.05 ± µM) has 1.7-fold higher effects than meglumine antimoniate (CC50 = 24.14 ± 2.6 µM). Treatment of the paw lesion in infected BALB/c mice with epoxymethoxy-lawsone led to a significant 27% reduction (p < 0.05) of the lesion size, for all administrated doses, compared to the control group. Lesion reduction was also detected after mice treatment with meglumine antimoniate, reaching 31.0% (0.23 mg of Sb(V)/Kg/day and 2.27 mg of Sb(V)/Kg/day) and 64.0% (22.7 mg of Sb(V)/Kg/day). In addition, mice lesion ultrastructural changes were evidenced in amastigotes. The set of data gathered here indicate that epoxymethoxylawsone has pronounced effects on parasites and merits furthering to the preclinical stage.
Assuntos
Antiprotozoários/administração & dosagem , Leishmaniose/tratamento farmacológico , Naftoquinonas/administração & dosagem , Animais , Antiprotozoários/química , Antiprotozoários/farmacologia , Modelos Animais de Doenças , Feminino , Leishmania/efeitos dos fármacos , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Meglumina/administração & dosagem , Meglumina/farmacologia , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Estrutura Molecular , Naftoquinonas/química , Naftoquinonas/farmacologia , Compostos Organometálicos/administração & dosagem , Compostos Organometálicos/farmacologiaRESUMO
The primary choice of drugs to treat Leishmaniasis are the pentavalent antimony-based compounds, nevertheless these drugs presented undesirable side effects. However, safe natural compounds could be used in combination with these drugs to enhance their activity. The aim of this study was to evaluate the sinergism of capsaicin and piperine, isolated from Capsicum frutescens and Piper nigrum, respectively, in combination with meglumine antimoniate against Leishmania infantum promastigote and amastigote forms. Each compound was mixed with the standard drug in several percentage mixtures and tested at various concentrations. Capsaicin and piperine in combination with meglumine antimoniate (25% + 75%) showed better anti-leishmanial activity with EC50â¯=â¯4.31⯱â¯0.44 e 7.25⯱â¯4.84⯵g/mL against promastigote and amastigote forms, respectively. The results point that these spice alkaloids are suitable compounds to be administered in combinations with antileishmanial drugs to improve their action.
Assuntos
Alcaloides/farmacologia , Antiprotozoários/farmacologia , Benzodioxóis/farmacologia , Capsaicina/farmacologia , Leishmania infantum/efeitos dos fármacos , Meglumina/farmacologia , Compostos Organometálicos/farmacologia , Piperidinas/farmacologia , Alcamidas Poli-Insaturadas/farmacologia , Alcaloides/uso terapêutico , Antiprotozoários/uso terapêutico , Benzodioxóis/uso terapêutico , Capsaicina/uso terapêutico , Cromatografia Líquida de Alta Pressão , Sinergismo Farmacológico , Concentração Inibidora 50 , Leishmaniose Visceral/tratamento farmacológico , Espectroscopia de Ressonância Magnética , Meglumina/uso terapêutico , Antimoniato de Meglumina , Compostos Organometálicos/uso terapêutico , Piperidinas/uso terapêutico , Alcamidas Poli-Insaturadas/uso terapêutico , Espectrofotometria UltravioletaRESUMO
Hepatic fibropoiesis in canine visceral leishmaniasis (CVL) were evaluated by histological (morphometrical collagen deposition) and immunohistochemical assays characterizing alpha-actin (α-SMA), vimentin, calprotectin (L1 antigen), and TGF-ß in 46 naturally infected dogs with Leishmania infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol separately and in combination. Six treatment groups were defined: meglumine antimoniate encapsulated in nanometric liposomes (LMA), allopurinol (ALLOP); liposome-encapsulated meglumine antomoniate combined with allopurinol (LMA+ALLOP); empty liposomes (LEMP); empty liposomes combined with allopurinol (LEMP+ALLOP) and saline. Relative liver weight was lower in LMA, LMA+ALLOP, and ALLOP groups compared to the LEMP control. Significantly lower granulomatous chronic inflammatory reaction was seen in the ALLOP group compared to a control group. Calprotectin was lowest in liver of those dogs showing lower numbers of intralobular hepatic granulomas. Collagen deposits were significantly higher in LMA compared to ALLOP, LEMP+ALLOP, and Saline groups. LMA+ALLOP group collagen deposition was higher than dogs treated only with allopurinol. Immunohistochemical analysis showed significant higher α-SMA in hepatic stellate cells (HSCs), hepatic perisinusoidal cells, in control groups than LMA+ALLOP and LEMP+ALLOP. Alpha-actin and Vimentin positive cells were diffusely distributed throughout the liver parenchyma in the hepatic lobule, mainly in HSCs. Vimentin expression was significantly higher in the saline group than in the ALLOP group. Our data suggest that allopurinol inhibits HSC and results in lower collagen deposits in liver during CVL progression, as supported by the significantly lower expression of TGF-ß in the ALLOP group compared to other groups. Results demonstrated that treatment with allopurinol inhibited chronic granulomatous inflammatory reaction and hepatic fibrosis in CVL.
Assuntos
Alopurinol/uso terapêutico , Doenças do Cão/tratamento farmacológico , Leishmaniose Visceral/veterinária , Cirrose Hepática/veterinária , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Alopurinol/farmacologia , Animais , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Cães , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Leishmania infantum , Leishmaniose Visceral/complicações , Leishmaniose Visceral/tratamento farmacológico , Lipossomos/administração & dosagem , Fígado/efeitos dos fármacos , Cirrose Hepática/etiologia , Masculino , Meglumina/farmacologia , Antimoniato de Meglumina , Compostos Organometálicos/farmacologia , Distribuição Aleatória , Fator de Crescimento Transformador beta/genética , Vimentina/genéticaRESUMO
The physicochemical properties of four N-halomethylated and one non-halomethylated ammonium salts, with proven in vitro antileishmanial activity, were determined according to pharmaceutical standard procedures. The effectiveness and toxicity of these compounds were assessed in hamsters infected with Leishmania (Viannia) braziliensis and compared to that showed by meglumine antimoniate. Animals were followed during 90 days after the completion of treatment. Therapeutic response was determined according to the reduction of size of skin lesions. Toxicity was determined by the effect of compounds on body weight changes and serum levels of renal and hepatic metabolites. The effectiveness of compound 4 was similar to that showed by intralesional administration of meglumine antimoniate and better than that of the other ammonium salts. Levels of creatinine, alanine amino transferase, and blood urea nitrogen in serum were not significantly different between treatment groups, including healthy or untreated hamsters. Results imply that compound 4 has potential as a pharmaceutical active ingredient in the development of new and better formulations for the treatment of cutaneous leishmaniasis.
Assuntos
Antiprotozoários/farmacologia , Leishmania braziliensis/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Compostos de Amônio Quaternário/farmacologia , Administração Tópica , Animais , Antiprotozoários/química , Peso Corporal/efeitos dos fármacos , Cricetinae , Modelos Animais de Doenças , Feminino , Leishmaniose Cutânea/parasitologia , Masculino , Meglumina/farmacologia , Antimoniato de Meglumina , Compostos Organometálicos/farmacologia , Compostos de Amônio Quaternário/química , Sais , Pele/parasitologia , Testes de ToxicidadeRESUMO
Background: Disbudding is often practiced in modern farm because of the reasons for the safekeeping of the animal, other animals lessen the risk of injury and less aggressive behavior. Without regard to the method of disbudding leads to disruption behavioral changes, cardiac and endocrine responses related pain of animals. Sedation, local anesthesia and analgesia are performed studies in order to eliminate of cardiac, endocrine, behavioral response which is caused by pain associated with disbudding. In this study, it was aimed to determine the effect on the oxidant and antioxidant system in the calves of disbudding by using the caustic paste with and without painkiller.Materials, Methods & Results: The animal material of the study was created 24 Simmentals calves in different sexes on average 2 weeks (± 2 days) and 50 kg (± 15 kg) live weight. The cases were randomly divided into 2 groups of 12 calves in each group. In the group I (analgesia group); caustic paste+painkiller (2.2 mg-1 flunixin meglumine intravenous, IV) and group II (non-analgesia group); as disbudding applied with caustic pasta application only were divided into 2 groups. In the I group, 15th min before the application, flunixin meglumine at a dose of 2.2 mg-1 was administered IV and the horn blunting was performed by caustic paste method. Blood samples were taken at 15, 30 and 60th min after completion of horn blunting and physiological findings were recorded. In group II, the horns of the calves were disbudding with the same technique (but no analgesia aplication). Blood samples were taken at 15, 30 and 60th min after completion of horn blunting and physiological findings were record. Cortisol, glucose, total oxidant capacity (TOC) and total antioxidant capacity (TAC), 8-hydroxy-2-deoxyguanosine (8-OHdG), glutathione (GSH), superoxide dismutase (SOD) enzymes measurements (ELISA) were performed in both groups.[...](AU)
Assuntos
Animais , Bovinos , Meglumina/farmacologia , Anti-Inflamatórios não Esteroides/farmacologia , Cornos/cirurgia , Estresse OxidativoRESUMO
Background: Disbudding is often practiced in modern farm because of the reasons for the safekeeping of the animal, other animals lessen the risk of injury and less aggressive behavior. Without regard to the method of disbudding leads to disruption behavioral changes, cardiac and endocrine responses related pain of animals. Sedation, local anesthesia and analgesia are performed studies in order to eliminate of cardiac, endocrine, behavioral response which is caused by pain associated with disbudding. In this study, it was aimed to determine the effect on the oxidant and antioxidant system in the calves of disbudding by using the caustic paste with and without painkiller.Materials, Methods & Results: The animal material of the study was created 24 Simmentals calves in different sexes on average 2 weeks (± 2 days) and 50 kg (± 15 kg) live weight. The cases were randomly divided into 2 groups of 12 calves in each group. In the group I (analgesia group); caustic paste+painkiller (2.2 mg-1 flunixin meglumine intravenous, IV) and group II (non-analgesia group); as disbudding applied with caustic pasta application only were divided into 2 groups. In the I group, 15th min before the application, flunixin meglumine at a dose of 2.2 mg-1 was administered IV and the horn blunting was performed by caustic paste method. Blood samples were taken at 15, 30 and 60th min after completion of horn blunting and physiological findings were recorded. In group II, the horns of the calves were disbudding with the same technique (but no analgesia aplication). Blood samples were taken at 15, 30 and 60th min after completion of horn blunting and physiological findings were record. Cortisol, glucose, total oxidant capacity (TOC) and total antioxidant capacity (TAC), 8-hydroxy-2-deoxyguanosine (8-OHdG), glutathione (GSH), superoxide dismutase (SOD) enzymes measurements (ELISA) were performed in both groups.[...]
Assuntos
Animais , Bovinos , Anti-Inflamatórios não Esteroides/farmacologia , Cornos/cirurgia , Estresse Oxidativo , Meglumina/farmacologiaRESUMO
BACKGROUND: Forty-four strains isolated from a cohort of cutaneous leishmaniasis (CL) patients who did or did not respond to one course of treatment with meglumine antimoniate were investigated to explore genetic polymorphisms in parasite kinetoplast DNA minicircles. Leishmania (Viannia) braziliensis strains isolated from responder (R) and non-responder (NR) patients who acquired infection in Rio de Janeiro or in other Brazilian states were studied using low-stringency single-specific primer polymerase chain reaction (LSSP-PCR) to identify genetic polymorphisms. RESULTS: Polymorphisms were observed in parasites recovered from patient lesions. No association was found between a specific genotype and R or NR patients. Phenetic analysis grouped the genotypes into three main clusters, with similarity indices varying from 0.72 to 1.00. Although no specific genotype association was detected, at least one group of L. (V.) braziliensis genotypes that circulates in Rio de Janeiro was discriminated in clusters I and III, showing phenotypes of good and poor responses to treatment, respectively. Cluster I comprised parasite profiles recovered from R patients from Rio de Janeiro and in cluster III, NR samples were prevalent. Cluster II comprised 24 isolates, with 21 from Rio de Janeiro and three from other states, equally distributed between R and NR patients. Additionally, we found that parasites sharing all common genetic characteristics acted differently in response to treatment. CONCLUSIONS: These results are of clinical-epidemiological importance since they demonstrate that populations of L. (V.) braziliensis that exhibit high levels of genetic similarity also display different phenotypes associated with meglumine antimoniate responses in cutaneous leishmaniasis patients.
Assuntos
Antiprotozoários/uso terapêutico , Leishmania braziliensis/classificação , Leishmania braziliensis/genética , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/parasitologia , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Adolescente , Adulto , Fatores Etários , Antiprotozoários/farmacologia , Brasil , Criança , Análise por Conglomerados , Estudos de Coortes , DNA de Cinetoplasto/genética , Eletroforese em Gel de Ágar , Feminino , Genótipo , Humanos , Leishmania braziliensis/efeitos dos fármacos , Masculino , Meglumina/farmacologia , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/farmacologia , Fenótipo , Projetos Piloto , Reação em Cadeia da Polimerase , Polimorfismo Genético , Adulto JovemRESUMO
Leishmaniasis remains a serious public health problem in developing countries without effective control, whether by vaccination or chemotherapy. Part of the failure of leishmaniasis control is due to the lack of new less toxic and more effective drugs able to eliminate both the lesions and the parasite. Oxiranes derived from naphthoquinones now being assayed are promising drugs for the treatment of this group of diseases. The predicted pharmacokinetic properties and toxicological profiles of epoxy-α-lapachone and epoxymethoxy-lawsone have now been compared to those of meglumine antimoniate, and histological changes induced by these drugs in noninfected BALB/c mice tissues are described. Effects of these compounds on liver, kidney, lung, heart, and cerebral tissues of healthy mice were examined. The data presented show that both these oxiranes and meglumine antimoniate induce changes in all BALB/c mice tissues, with the lung, heart, and brain being the most affected. Epoxymethoxy-lawsone was the most toxic to lung tissue, while most severe damage was caused in the heart by epoxy-α-lapachone. Meglumine antimoniate caused mild-to-moderate changes in heart and lung tissues.
Assuntos
Compostos de Epóxi/efeitos adversos , Leishmaniose/tratamento farmacológico , Meglumina/efeitos adversos , Compostos Organometálicos/efeitos adversos , Animais , Compostos de Epóxi/farmacologia , Meglumina/farmacologia , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , Especificidade de Órgãos , Compostos Organometálicos/farmacologiaRESUMO
Current strategies to control leishmaniasis are mainly based on chemotherapy. However, none of the available drugs can be considered to be ideal to treat this disease. Because of the hydrophobic nature and bioactivities of their components, essential oils (EOs) can be considered as important sources for developing agents against intracellular pathogens, such as Leishmania parasites. In this study, we report the chemical characterization, antileishmanial activities, and cytotoxicity effect of the EO from Pluchea carolinensis (Jacq.) G. Don. (Asteraceae). Chemical analysis revealed that EO from aerial part from P. carolinensis is composed of 44 compounds. The main component was selin-11-en-4α-ol, which made up 51.0%. In vitro antileishmanial studies showed that P. carolinensis EO inhibited the growth of promastigotes (IC50 = 24.7 ± 7.1 µg/mL) and amastigotes (IC50 = 6.2 ± 0.1 µg/mL) of Leishmania amazonensis, while cytotoxicity evaluation revealed fivefold higher values than those for the parasites. In a model of experimental cutaneous leishmaniasis in BALB/c mice, five doses of EO at 30 mg/kg by intralesional route demonstrated smaller lesion size and parasite burden (p < 0.05) compared with animals treated with Glucantime® and untreated mice. In conclusion, in vitro and in vivo results showed the potentialities of EO from P. carolinensis with the future possibility of a new alternative in the treatment for leishmaniasis. Copyright © 2017 John Wiley & Sons, Ltd.
Assuntos
Antiprotozoários/farmacologia , Asteraceae/química , Leishmaniose Cutânea/tratamento farmacológico , Óleos Voláteis/farmacologia , Animais , Feminino , Leishmania/efeitos dos fármacos , Leishmania mexicana/efeitos dos fármacos , Meglumina/farmacologia , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , Compostos Organometálicos/farmacologia , Folhas de Planta/químicaRESUMO
Leishmaniasis is a neglected tropical disease that affects millions of people worldwide and represents a major public health problem. Information on protein expression patterns and functional roles within the context of Leishmania-infected human monocyte-derived macrophages (MDMs) under drug treatment conditions is essential for understanding the role of these cells in leishmaniasis treatment. We analyzed functional changes in the expression of human MDM genes and proteins during in vitro infection by Leishmania braziliensis and treatment with Glucantime (SbV), using quantitative PCR (qPCR) arrays, Western blotting, confocal microscopy, and small interfering RNA (siRNA) human gene inhibition assays. Comparison of the results from gene transcription and protein expression analyses revealed that glutathione S-transferase π1 (GSTP1), glutamate-cysteine ligase modifier subunit (GCLM), glutathione reductase (GSR), glutathione synthetase (GSS), thioredoxin (TRX), and ATP-binding cassette, subfamily B, member 5 (ABCB5), were strongly upregulated at both the mRNA and protein levels in human MDMs that were infected and treated, compared to the control group. Subcellular localization studies showed a primarily phagolysosomal location for the ABCB5 transporter, indicating that this protein may be involved in the transport of SbV By inducing a decrease in L. braziliensis intracellular survival in THP-1 macrophages, siRNA silencing of GSTP1, GSS, and ABCB5 resulted in an increased leishmanicidal effect of SbV exposure in vitro Our results suggest that human MDMs infected with L. braziliensis and treated with SbV express increased levels of genes participating in antioxidant defense, whereas our functional analyses provide evidence for the involvement of human MDMs in drug detoxification. Therefore, we conclude that GSS, GSTP1, and ABCB5 proteins represent potential targets for enhancing the leishmanicidal activity of Glucantime.
Assuntos
Leishmania braziliensis/efeitos dos fármacos , Leishmania braziliensis/patogenicidade , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Meglumina/farmacologia , Compostos Organometálicos/farmacologia , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Antioxidantes/metabolismo , Glutamato-Cisteína Ligase/metabolismo , Glutationa Redutase/metabolismo , Glutationa S-Transferase pi/metabolismo , Glutationa Sintase/metabolismo , Interações Hospedeiro-Patógeno , Humanos , Antimoniato de Meglumina , Reação em Cadeia da PolimeraseRESUMO
INTRODUCTION: Reports of therapeutic failure to meglumine antimoniate (MA) and miltefosine in cutaneous leishmaniasis (CL) varies between species, populations and geographic regions. This study aimed to determine the clinical, drug-related factors, and Leishmania species associated with treatment failure in children and adults with cutaneous leishmaniasis. METHODS: A cohort study was performed with children (2-12 years old) and adults (18-65 years old) with CL, who have participated in clinical studies at CIDEIM Cali, Tumaco and Chaparral. Incidence of therapeutic failure was estimated by treatment and age groups. Descriptive, bivariate, and multiple logistic regression analyses were performed for the complete cohort and pediatric patients. RESULTS: Two hundred and thirty patients were included (miltefosine: 112; MA: 118), of which 60.4% were children and 83.9% were infected with L.V. panamensis. Overall incidence of therapeutic failure was 15.65% (95%CI: 10.92-20.38), and was lower for miltefosine than for MA (8.92%, 95%CI: 3.59-14.26 versus 22.03%, 95%CI:14.48-29.58, p = 0.006). Treatment failure was associated with age ≤8 years (OR: 3.29; 95%CI: 1.37-7.89), disease duration ≤1 month (OR: 3.29; 95%CI: 1.37-7.89), regional lymphadenopathy (OR: 2.72; 95%CI: 1.10-6.70), treatment with MA (OR: 3.98; 95%CI: 1.66-9.50), and adherence <90% (OR: 3.59; 95%CI: 1.06-12.11). In children, higher Z-score of height/age was a protective factor (OR: 0.58; 95%CI: 0.36-0.93), while treatment with MA was a risk factor (OR: 40.82; 95%CI: 2.45-677.85), demonstrating significant interaction with age (p = 0.03). CONCLUSIONS: Clinical and drug-related factors determine therapeutic failure in CL. High risk of failure in children treated with MA indicates the need to reconsider this drug as first line treatment in this population. TRIAL REGISTRATION: Clinical trial registration: NCT00487253 Clinical trial registration: NCT01462500 Clinical trial registration: NCT01464242.
Assuntos
Antiprotozoários/uso terapêutico , Leishmania/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Fosforilcolina/análogos & derivados , Adolescente , Adulto , Antiprotozoários/farmacologia , Criança , Pré-Escolar , Estudos de Coortes , Colômbia , Feminino , Humanos , Leishmaniose Cutânea/parasitologia , Masculino , Meglumina/farmacologia , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/farmacologia , Fosforilcolina/farmacologia , Fosforilcolina/uso terapêutico , Fatores de Risco , Falha de Tratamento , Adulto JovemRESUMO
AbstractAnti-leishmaniasis drug resistance is a common problem worldwide. The aim of this study was to inventory the general in vitro level of sensitivity of Leishmania isolates circulating in French Guiana and to highlight potential in vitro pentamidine-resistant isolates. This sensitivity study was conducted on 36 patient-promastigote isolates for seven drugs (amphotericin B, azithromycin, fluconazole, meglumine antimoniate, miltefosine, paromomycin, and pentamidine) using the Cell Counting Kit-8 viability test. The IC50 values obtained were heterogeneous. One isolate exhibited high IC50 values for almost all drugs tested. Pentamidine, which is the first-line treatment in French Guiana, showed efficacy at very low doses (mean of 0.0038 µg/mL). The concordance of the in vitro pentamidine results with the patients' clinical outcomes was 94% (K = 0.82).
Assuntos
Antiprotozoários/farmacologia , Leishmania braziliensis/efeitos dos fármacos , Leishmania guyanensis/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Pentamidina/farmacologia , Anfotericina B/farmacologia , Azitromicina/farmacologia , Resistência a Medicamentos , Fluconazol/farmacologia , Humanos , Leishmania braziliensis/crescimento & desenvolvimento , Leishmania braziliensis/isolamento & purificação , Leishmania guyanensis/crescimento & desenvolvimento , Leishmania guyanensis/isolamento & purificação , Leishmaniose Cutânea/parasitologia , Meglumina/farmacologia , Antimoniato de Meglumina , Compostos Organometálicos/farmacologia , Testes de Sensibilidade Parasitária , Paromomicina/farmacologia , Fosforilcolina/análogos & derivados , Fosforilcolina/farmacologia , Resultado do TratamentoRESUMO
The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate (DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory response at the infection site, as well as the production of both IFN-γ and TNF. Combination of topical BC-DETC plus intraperitoneal Sbv also significantly reduced disease development and parasite load. The leishmanicidal effect of BC-DETC was extended to human macrophages infected with L. braziliensis, highlighting the feasibility of BC-DETC as a topical formulation for chemotherapy of cutaneous leishmaniasis caused by L. braziliensis.
Assuntos
Antiprotozoários/farmacologia , Celulose/química , Ditiocarb/farmacologia , Leishmania braziliensis/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/farmacologia , Compostos Organometálicos/farmacologia , Administração Cutânea , Animais , Antiprotozoários/química , Celulose/isolamento & purificação , Citocinas/biossíntese , Ditiocarb/química , Quimioterapia Combinada , Feminino , Gluconacetobacter/química , Humanos , Injeções Intraperitoneais , Leishmania braziliensis/crescimento & desenvolvimento , Leishmaniose Cutânea/metabolismo , Leishmaniose Cutânea/parasitologia , Macrófagos/efeitos dos fármacos , Macrófagos/parasitologia , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , Cultura Primária de Células , Superóxido Dismutase-1/metabolismo , Superóxidos/metabolismoRESUMO
BACKGROUND: American cutaneous leishmaniasis (ACL) is a complicated disease producing about 67.000 new cases per year. The severity of the disease depends on the parasite species; however in the vast majority of cases species confirmation is not feasible. WHO suggestion for ACL produced by Leishmania braziliensis, as first line treatment, are pentavalent antimonial derivatives (Glucantime or Sodium Stibogluconate) under systemic administration. According to different authors, pentavalent antimonial derivatives as treatment for ACL show a healing rate of about 75% and reasons for treatment failure are not well known. METHODS: In order to characterise the clinical and parasitological features of patients with ACL that did not respond to Glucantime, a cross-sectional observational study was carried out in a cohort of 43 patients recruited in three of the Colombian Army National reference centers for complicated ACL. Clinical and paraclinical examination, and epidemiological and geographic information were recorded for each patient. Parasitological, histopathological and PCR infection confirmation were performed. Glucantime IC50 and in vitro infectivity for the isolated parasites were estimated. RESULTS: Predominant infecting Leishmania species corresponds to L. braziliensis (95.4%) and 35% of the parasites isolated showed a significant decrease in in vitro Glucanatime susceptibility associated with previous administration of the medicament. Lesion size and in vitro infectivity of the parasite are negatively correlated with decline in Glucantime susceptibility (Spearman: r = (-)0,548 and r = (-)0,726; respectively). CONCLUSION: A negative correlation between lesion size and parasite resistance is documented. L. braziliensis was found as the main parasite species associated to lesion of patients that underwent treatment failure or relapse. The indication of a second round of treatment in therapeutic failure of ACL, produced by L. braziliensis, with pentavalent antimonial derivatives is discussable.
Assuntos
Antiprotozoários/uso terapêutico , Leishmania braziliensis/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Meglumina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Adulto , Antiprotozoários/farmacologia , Estudos de Coortes , Estudos Transversais , Humanos , Concentração Inibidora 50 , Leishmania braziliensis/fisiologia , Masculino , Meglumina/farmacologia , Antimoniato de Meglumina , Compostos Organometálicos/farmacologia , Recidiva , Falha de Tratamento , Células U937 , Adulto JovemRESUMO
INTRODUCTION: Leishmaniasis is a disease caused by the protozoan Leishmania that resides mainly in mononuclear phagocytic system tissues. Pentavalent antimonials are the main treatment option, although these drugs have toxic side effects and high resistance rates. A potentially alternative and more effective therapeutic strategy is to use liposomes as carriers of the antileishmanial agents. The aims of this study were to develop antimonial drugs entrapped into phosphatidylserine liposomes and to analyze their biological and physicochemical characteristics. METHODS: Liposomes containing meglumine antimoniate (MA) or pentavalent antimony salt (Sb) were obtained through filter extrusion (FEL) and characterized by transmission electron microscopy. Promastigotes of Leishmania infantum were incubated with the drugs and the viability was determined with a tetrazolium dye (MTT assay). The effects of these drugs against intracellular amastigotes were also evaluated by optical microscopy, and mammalian cytotoxicity was determined by an MTT assay. RESULTS: Liposomes had an average diameter of 162nm. MA-FEL showed inhibitory activity against intracellular L. infantum amastigotes, with a 50% inhibitory concentration (IC50) of 0.9µg/mL, whereas that of MA was 60µg/mL. Sb-FEL showed an IC50 value of 0.2µg/mL, whereas that of free Sb was 9µg/mL. MA-FEL and Sb-FEL had strong in vitro activity that was 63-fold and 39-fold more effective than their respective free drugs. MA-FEL tested at a ten-times higher concentration than Sb-FEL did not show cytotoxicity to mammalian cells, resulting in a higher selectivity index. CONCLUSIONS: Antimonial drug-containing liposomes are more effective against Leishmania-infected macrophages than the non-liposomal drugs.
Assuntos
Gluconato de Antimônio e Sódio/farmacologia , Antiprotozoários/farmacologia , Leishmania infantum/efeitos dos fármacos , Macrófagos Peritoneais/parasitologia , Meglumina/farmacologia , Compostos Organometálicos/farmacologia , Fosfatidilserinas/farmacologia , Animais , Gluconato de Antimônio e Sódio/química , Antiprotozoários/química , Cricetinae , Relação Dose-Resposta a Droga , Concentração Inibidora 50 , Lipossomos , Meglumina/química , Antimoniato de Meglumina , Camundongos , Camundongos Endogâmicos BALB C , Compostos Organometálicos/química , Testes de Sensibilidade Parasitária , Fosfatidilserinas/químicaRESUMO
Abstract: INTRODUCTION: Leishmaniasis is a disease caused by the protozoan Leishmania that resides mainly in mononuclear phagocytic system tissues. Pentavalent antimonials are the main treatment option, although these drugs have toxic side effects and high resistance rates. A potentially alternative and more effective therapeutic strategy is to use liposomes as carriers of the antileishmanial agents. The aims of this study were to develop antimonial drugs entrapped into phosphatidylserine liposomes and to analyze their biological and physicochemical characteristics. METHODS: Liposomes containing meglumine antimoniate (MA) or pentavalent antimony salt (Sb) were obtained through filter extrusion (FEL) and characterized by transmission electron microscopy. Promastigotes of Leishmania infantum were incubated with the drugs and the viability was determined with a tetrazolium dye (MTT assay). The effects of these drugs against intracellular amastigotes were also evaluated by optical microscopy, and mammalian cytotoxicity was determined by an MTT assay. RESULTS: Liposomes had an average diameter of 162nm. MA-FEL showed inhibitory activity against intracellular L. infantum amastigotes, with a 50% inhibitory concentration (IC50) of 0.9μg/mL, whereas that of MA was 60μg/mL. Sb-FEL showed an IC50 value of 0.2μg/mL, whereas that of free Sb was 9μg/mL. MA-FEL and Sb-FEL had strong in vitro activity that was 63-fold and 39-fold more effective than their respective free drugs. MA-FEL tested at a ten-times higher concentration than Sb-FEL did not show cytotoxicity to mammalian cells, resulting in a higher selectivity index. CONCLUSIONS: Antimonial drug-containing liposomes are more effective against Leishmania-infected macrophages than the non-liposomal drugs.
Assuntos
Animais , Compostos Organometálicos/farmacologia , Fosfatidilserinas/farmacologia , Macrófagos Peritoneais/parasitologia , Leishmania infantum/efeitos dos fármacos , Gluconato de Antimônio e Sódio/farmacologia , Meglumina/farmacologia , Antiprotozoários/farmacologia , Compostos Organometálicos/química , Fosfatidilserinas/química , Cricetinae , Gluconato de Antimônio e Sódio/química , Concentração Inibidora 50 , Testes de Sensibilidade Parasitária , Relação Dose-Resposta a Droga , Antimoniato de Meglumina , Lipossomos , Meglumina/química , Camundongos , Camundongos Endogâmicos BALB C , Antiprotozoários/químicaRESUMO
During Leishmania infection, host immune response is important to prevent the growth/survival of intracellular amastigotes. In this study, we evaluated in vitro and in vivo whether or not during Leishmania amazonensis infection, pentavalent antimonial treatment/therapy could be more effective under TNF-α inhibition. Both L. amazonensis-infected macrophages (in vitro model) and mice (in vivo model) were treated with a nuclear factor-κB (NF-κB) inhibitor and with Glucantime®, alone and in combined administrations. The in vitro amastigote counts, cytokines and nitrites' production were assessed after 48h incubation with the drugs. Paw lesion sizes and amastigote counts were also evaluated in vivo. Quantification of IL-1ß from the infected tissue was performed. In vitro results show that when infected macrophages were incubated with QNZ+Glucantime®, a greater clearance was observed for the amastigotes' growth and this was related to greater nitrite production compared to the group that was only infected. In vivo results show that mice that received the combined treatment had their paw lesion sizes and amastigote nests inside the macrophages greatly diminished, correlating with increased IL-1ß levels.